OptimizeRx Affirms FY2026 Sales Guidance of $95.000M-$100.000M vs $97.427M Est

Benzinga Newsdesk www.benzinga.com Negative 44.8%

Neg 44.8% Neu 0% Pos 0%

OptimizeRx (NASDAQ:OPRX) affirms FY2026 sales outlook from $95.000 million-$100.000 million to $95.000 million-$100.000 million vs $97.427 million estimate.